Kyverna Therapeutics Inc.
KYTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$511.9M
Close$
$2.15
76% downside
Current Fair Value
76% downsideOvervalued by 76% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $511.90 Million |
|---|---|
| Enterprise Value | $494.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.64 |
| Beta | 1.94 |
| Outstanding Shares | 60,896,872 |
Return
| Return on Equity | -92.20% |
|---|---|
| Return on Assets | -69.44% |
| Return on Invested Capital | -79.67% |
Valuation & Multiples
| P/E Ratio | -2.86 |
|---|---|
| PEG | 32.04 |
| Price to Sales | - |
| Price to Book Ratio | 4.48 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.15 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.70
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.68
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2542▼ 90.51% |
|---|---|
| Total Calls | 131,016▲ 41.95% |
| Total Puts | 33,300▼ 68.88% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 73.85%▲ 1.43% |
|---|---|
| Total Invested | $300.53M▼ 6.36% |
| Investors Holding | 116▲ 10.00% |
ESG Score
No data